PLUS1
1.30
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Seelos Therapeutics Inc | SEEL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.28 | 27.45% | 1.30 | 1.03 | 1.39 | 1.03 | 1.02 | 19:59:48 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 1.29 | 1.30 | 0.01 | 0.77% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 8,576 | 4,096,872 | $ 1.17 | $ 4,779,902 | 1,817,914 | 0.4195 - 3.25 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:36 | 50 | $ 1.30 | USD |
Seelos Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 58.43M | 44.95M | 29.36M | $ 375.00k | $ - | -4.47 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 1.00 | 35.40% |
Seelos Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/21/2020 | 16:17 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) |
| 5/21/2020 | 06:02 | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) |
| 5/19/2020 | 09:01 | GlobeNewswire Inc. | Seelos Therapeutics to Host Key Opinion Leader Call to.. |
| 5/19/2020 | 08:31 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/18/2020 | 08:01 | GlobeNewswire Inc. | Seelos Therapeutics to Participate in the Benchmark.. |
| 5/15/2020 | 17:20 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/15/2020 | 17:00 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SEEL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.79 | 1.39 | 0.72 | 0.9714371 | 3,408,562 | 0.51 | 64.56% |
| 1 Month | 0.4827 | 1.39 | 0.479 | 0.7895032 | 2,146,216 | 0.8173 | 169.32% |
| 3 Months | 0.80 | 1.39 | 0.4195 | 0.7122902 | 1,137,022 | 0.50 | 62.5% |
| 6 Months | 0.8524 | 1.90 | 0.4195 | 0.8995847 | 944,215 | 0.4476 | 52.51% |
| 1 Year | 2.68 | 3.25 | 0.4195 | 1.12 | 651,407 | -1.38 | -51.49% |
| 3 Years | 4.02 | 8.00 | 0.4195 | 2.36 | 1,401,680 | -2.72 | -67.66% |
| 5 Years | 4.02 | 8.00 | 0.4195 | 2.36 | 1,401,680 | -2.72 | -67.66% |
Seelos Therapeutics Description
| Seelos Therapeutics Inc is engaged in the pharmaceutical industry. The company's pipeline products include SLS-002 which is intranasal racemic ketamine for patients with suicidality in post-traumatic stress disorder and depressive disorder; SLS-006 which is a small molecule, partial dopamine agonist for Parkinson's Disease; and SLS-005 is Trehalose, a protein stabilizer. Its other pipeline products include SLS-007, SLS-008, SLS-004, SLS-010, and SLS-012. |
